BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

COVAX nearing $2B fund-raising goal for equitable vaccine distributionThe U.K., Canada, Germany, Italy and Sweden pledged $958 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC), which seeks to ensure equitable access to COVID-19...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

...MBT-001 inhibits immuno-suppressive signals induced downstream of CD47 via its interaction with the secreted glycoprotein TSP-1...
...TSP-1 makes the tumor microenvironment hostile to cancer growth. Schwartz said the data on whether TSP-1...
...SIRPA (CD172a; SHPS-1) - Signal regulatory protein α TSP-1 (THBS1) - Thrombospondin-1 Karen Tkach Tuzman, Associate Editor CD47 SIRPA TSP-1...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jul 15, 2019
Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD, and ensures its independence into the next decade. Under the...
BioCentury | May 31, 2019
Company News

Vigeo debuts to reprogram tumor microenvironment

...an undisclosed surface receptor on myeloid-derived suppressor cells, triggering production of TSP-1. According to Watnick, TSP-1...
...at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Novartis AG (NYSE:NVS; SIX:NOVN). While the antitumor properties of TSP-1...
...Inc. (NASDAQ:VSTM), Bind Therapeutics Inc. and Intellikine Inc. Targets: PSAP - Prosaposin; TSP-1 (THBS1) - Thrombospondin-1 Elizabeth...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...immune signaling. Tempest also showed TPST-1120’s antitumor activity required the matrix glycoprotein TSP-1. TPST-1120 boosted TSP-1...
...me signal” on tumor cells and inhibits angiogenesis. Dubensky thinks the effects of TPST-1120 on TSP-1...
...Prostaglandin E2 receptor EP4 subtype STING (TMEM173) - Transmembrane protein 173 TSP-1 (THBS1) - Thrombospondin-1 Lauren...
BioCentury | Aug 9, 2018
Distillery Techniques

Drug platforms

...convertase (NRDC) or the combination of chemokine CC motif ligand 5 (RANTES; CCL5), thrombospondin-1 (TSP-1; THBS1...
...IGF) binding protein 2 (IGFBP2) Macrophage migration inhibitory factor (MIF) Plasminogen activator inhibitor 1 (SERPINE1) (PAI1) Thrombospondin-1 (TSP-1) (THBS1) Hematology...
BioCentury | May 11, 2018
Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
Items per page:
1 - 10 of 76